重组人血管内皮抑制素联合顺铂胸腔灌注治疗晚期非小细胞肺癌恶性胸腔积液的临床疗效

Clinical Hfficacy of Pleural Perfusion with Recombinant Human Endostatin Combined with Cisdiammi Dichloride Platinum for Advanced Non-small Cell Lung Cancer Patients with Malignant Pleural Effusion

目的观察重组人血管内皮抑制素(恩度)联合顺铂治疗晚期非小细胞肺癌(NSCLC)恶性胸腔积液的临床疗效和不良反应。方法 90例晚期NSCLC合并恶性胸腔积液患者随机分为联合组(45例)和顺铂组(45例),联合组胸腔内注入恩度45 mg+顺铂40 mg/m2,2次/周,连续3周;顺铂组单用顺铂40 mg/m2胸腔灌注治疗,2次/周,连续3周。评价近期疗效、生活质量(QOL)和不良反应。结果联合组客观有效率(RR)82.22%;顺铂组为51.11%(P<0.05);联合组QOL改善有36例(80.00%),顺铂组为20例(44.44%)(P<0.05)。2组不良反应比较差异无统计学意义。结论恩度联合顺铂治疗晚期NSCLC胸腔积液疗效显著,可明显改善患者的生活质量,且不良反应小。

Objective To observe the clinical efficacy and adverse reactions of recombinant human endostatin ( en-dostar) combined with cisdiammi dichloride platinum (cDDP) in the treatment of advanced non-small cell lung cancer(NSCLC) patients with malignant pleural effusion .Methods 90 cases of advanced NSCLC patients with malignant pleural effusion were randomly divided into the combination group (endostar combined with cDDP)and the cDDP group,each with 45 cases.The combi-nation group was performed pleural perfusion of endostar 45 mg and cDDP 40 mg/m2 ,twice a week for 3 weeks .The control group was only given pleural perfusion of cDDP 40 mg/m2,twice a week for 3 weeks.The efficacy,quality of life(QOL),and adverse re-actions were evaluated.Results The recovery rate(RR)of the combination group was 82.22%,and 51.11% for the control group(P<0.05).36(80.00%)patients in the combination group reported improved QOL ,while there were only 20(44.44%)in the control group(P<0.05).The differences of adverse reactions in both groups had no statistical significance .Conclusion Pleural perfusion of endostar combined with cDDP is a safe and feasible way to treat advanced NSCLC patients with malignantpleural effusion,it can improve QOL of patients with mild adverse reactions .